Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024

Eur Urol. 2021 Mar;79(3):e83-e84. doi: 10.1016/j.eururo.2020.12.016. Epub 2020 Dec 23.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • DNA Repair
  • Humans
  • Male
  • Phthalazines / adverse effects
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / genetics
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Prostatic Neoplasms, Castration-Resistant* / genetics

Substances

  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • olaparib